Press Releases May 12, 2026 04:05 PM

Lifecore Biomedical to Participate at CDMO Live Europe

Lifecore Biomedical to showcase expertise at CDMO Live Europe conference

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
LFCR

Lifecore Biomedical, a US-based injectable CDMO, announced its participation in the CDMO Live Europe conference held in Rotterdam. The company will engage in panel discussions and meetings to present its capabilities in sterile injectable pharmaceutical product development and manufacturing, focusing on process development and manufacturing services.

Lifecore Biomedical to Participate at CDMO Live Europe
LFCR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lifecore will participate in a key industry conference, CDMO Live Europe, including a panel on tech transfer strategies.
  • The company specializes in sterile injectable pharmaceutical products and is a leading manufacturer of injectable-grade hyaluronic acid.
  • Participation aims to strengthen relationships with prospective customers and showcase manufacturing expertise, supporting the biopharmaceuticals sector.

CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at CDMO Live Europe. The conference will take place May 19-21, 2026, in Rotterdam, Netherlands.

Details regarding Lifecore’s participation are as follows:

  • CDMO Live Europe
    Details: Ryan Swanson, Ph.D., Lifecore’s director of manufacturing science and technology, will participate in a panel discussion, and the company will host meetings with prospective customers to discuss process development and manufacturing services for injectables programs.
    Panel Title: The Tech Transfer Playbook: Right First Time Strategies
    Panel Date/Time: May 19, 2026, 13:40 to 15:00
    Booth: Booth G-1
    Conference Dates/Location: May 19-21, 2026, in Rotterdam, Netherlands

If you are interested in meeting with Lifecore during CDMO Live Europe, please reach out to us at: cdmo@lifecore.com.

About Lifecore Biomedical 
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com

Jennifer Arcure (Media)
917-603-0681
jarcure@vidasp.com

Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
ryan.lake@lifecore.com


Risks

  • Outcomes depend on successful customer engagement and converting interest into contracts in a competitive CDMO market.
  • Participation in a conference is unlikely to generate immediate revenue impact, posing short-term uncertainty.
  • Broader pharmaceutical and CDMO industry dynamics, including pricing pressures and regulatory changes, could affect future growth prospects.

More from Press Releases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress Jun 14, 2026 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026